Purpose: In the present study, we aimed to investigate the role of baseline, interim and endof treatment positron emission tomography/computed tomography (PET/CT) in assessing the prognosis of follicular lymphoma (FL). Methods: A total of 84 FL patients were retrospectively analyzed in this study. Baseline (n=59), interim (n=24, after 2-4 cycles) and end-of treatment (n=43) PET/CT images were re-evaluated, and baseline maximum standardized uptake value (SUV max ), total metabolic tumor volume (tMTV) and total lesion glycolysis (TLG) were recorded. Interim (I-PET) and end-of treatment (E-PET) PET/CT responses were interpreted by Deauville five-point scale (D-5PS) and International Harmonization Project criteria (IHP). Survival curves were calculated by KaplanMeier curves, and differences between groups were compared by log-rank test. Results: The 2-year progression-free survival (PFS) of the high-and low-TLG groups was 57.14% and 95.56%, respectively (p=0.0001). The 2-year overall survival (OS) of the highand low-TLG groups was 62.50% and 100%, respectively (p<0.0001). Multivariate analysis showed that TLG was an independent prognostic factor for PFS (p=0.001, HR=6.577, 95% CI=2.167-19.960) and OS (p=0.030, HR=19.291, 95% CI =2.689-137.947). Besides, Eastern Cooperative Oncology Group (ECOG) was the independent prognostic factor for OS (HR=8.924, 95% CI=1.273-62.559, p=0.028). Interim PET results based on D-5PS or IHP criteria were not significantly correlated with PFS (all p>0.05). However, E-PET results using D-5PS and IHP criteria were statistically significant (p=0.0001 and p=0.006). The D-5PS showed stronger prognostic value compared with IHP criteria. The optimal cutoff value of ΔSUV max % was 66.95% according to I-PET and 68.97% according to E-PET. However, only the ΔSUV max % from the baseline to the end-of therapy yielded statistically significant results in the prediction of PFS (p=0.0002). Conclusion: Our findings indicated that the baseline TLG and E-PET results were significantly associated with prognosis in patients with FL.
Introduction
Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma (NHL) in Western countries, accounting for approximately 20% to 25% of NHL. 1 Although rituximab in combination with chemotherapy has improved the prognosis of FL patients, approximately 20% of patients have relapse within 2 years after first-line treatment, with a 5-year overall survival (OS) rate of only 50%. 2, 3 However, these patients are not easily identified by current clinical indices of risk, such as the Follicular Lymphoma International Prognostic Index (FLIPI) or FLIPI2
scores. Therefore, early identification of high-risk factors that have a strong prognostic value for progression is particularly important. The role of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT) in the staging and response assessment of lymphoma has been widely established. [4] [5] [6] The maximum standardized uptake value (SUV max ) is the most widely studied parameter for assessing disease activity in lymphoma. 7 However, reliability is affected by partial volume effect, blood glucose level and time after injection. 8 Recently, several studies have
shown that metabolic tumor volume (MTV) and total lesion glycolysis (TLG) are promising prognostic indices in lymphoma, such as diffuse large B-cell lymphoma (DLBCL) 4, 9 and Hodgkin lymphoma (HL) 10 However, only very few studies have investigated the prognostic value of baseline total MTV and TLG in FL patients. The International Harmonization Project criteria (IHP) and the Deauville five-point scale (D-5PS) are commonly used to assess treatment outcome during and after first-line therapy. 11, 12 However, the roles of interim PET/CT and end-of treatment PET/CT in determining the prognosis still remain controversial. 11, 13, 14 In the present study, we aimed to investigate the prognostic value of semi-quantitative parameters, tMTV, TLG and SUV max, measured at baseline 18 F-FDG PET/CT in FL. We also compared the two different criteria (D-5PS and IHP) for exploring the prognostic value of interim and end-of treatment 18 F-FDG PET/CT.
Materials and methods Patients
A retrospective analysis was performed in the present study, which consisted of 84 FL patients (age 25-80 years, mean age of 51 years) who were diagnosed between March 2013 and December 2018. Inclusion criteria were as follows: (1) age ≥18 years, (2) histologically confirmed as FL, (3) patients who underwent baseline PET/CT (B-PET), or/and interim PET/CT (I-PET) after 2-4 cycles of chemotherapy, or/and end-of treatment PET/CT (E-PET) after all planned first-line therapy. Of the enrolled patients, 70 patients received (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) R-CHOP/R-CHOP-like regimens, eight patients didn't receive treatment due to lack of indications, and six patients were treated with other treatment regimens, including R-FM (rituximab, fludarabine and mitoxantrone), R-CVP (rituximab, cyclophosphamide, vincristine and prednisone) and rituximab alone.
This study was approved by the institutional review board of the First Affiliated Hospital of Soochow University. Trial registration number: ChiCTR1900023183. Because the trial was a retrospective study, written informed consent for this study was waived by the ethics committee, and no personal information was disclosed. This study was in accordance with the Declaration of Helsinki.
PET/CT acquisition
All the FDG PET/CT images were obtained from the US GE Discovery STE 16 PET/CT scanner. The patients were fasted for at least 6 h prior to the intravenous injection of 18 F-FDG (4.07-5.55 M Bq/kg), and the blood glucose level was lower than 11 mmol/L. After intravenous injection of 18 F-FDG for an average of 60±10 min, imaging data were obtained using low-dose CT (140 kV, 120 mA, transaxial FOV 70 cm, pitch 1.75, rotation time 0.8 s, slice thickness 3.75 mm), followed by PET emission images, 2-3 min per bed position. Whole body CT and PET images were obtained on the Xeleris Functional Imaging workstation, and the coronal, axial and sagittal slices PET/CT fusion images were obtained by iterative reconstruction.
Image analysis
All PET/CT images were reviewed by two experienced nuclear medicine physicians using the Advantage Workstation 4.3_05 (AW4.3_05). In baseline PET, the highest FDG uptake was considered to be the SUV max of the patient. For the interim PET/CT and end-of PET/CT images, SUV max was measured in residual lesions. If the lesion was disappeared after treatment, a region of interest was drawn in the same area on the baseline PET. The percentage change of SUV max was calculated using the following equation: ΔSUV max % = [SUV max (baseline)-SUV max (post-therapy)]/SUV max (baseline)×100. A threshold of 41% SUV max was used to delineate the metabolic tumor volume (MTV), as recommended by the European Association of Nuclear Medicine. 16 Total MTV (tMTV) referred to the sum of MTV of all lesions, and TLG was the sum of the product of MTV and its SUV mean in each lesion. Bone marrow involvement was considered in volume measurement only if there was focal uptake. Splenic involvement was considered if there was focal uptake or diffuse uptake higher than 150% of the liver background.
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The interim and end-of treatment PET/CT results were assessed according to the IHP 18 and D-5PS 19 criteria. For IHP criteria, FDG uptake greater than the uptake of the mediastinum in lesions greater than or equal to 2 cm and more than the adjacent background tissue in lesions less than 2 cm represented residual disease. The D-5PS scoring system was used to qualitatively evaluate the treatment response as follows: (1) no uptake; (2) uptake ≤ mediastinal blood pool; (3) uptake > mediastinal blood pool, but ≤ liver; (4) uptake moderately increased compared with the liver uptake at any site; (5) uptake markedly increased compared with the liver at any site. Scores of 4-5 were considered positive, while scores of 1-3 were considered negative.
Statistical analysis
All statistical analyses were performed using SPSS software (version 22, Chicago, IL Correlations between clinical characteristics and SUV max , tMTVor TLG were assessed using the Spearman correlation test. The suitable cutoff points of SUV max , tMTV, TLG and ΔSUV max % were obtained using the receiver operating characteristic (ROC) curve, and the area under the curve (AUC) was calculated. Progression-free survival (PFS) was defined from diagnosis to disease progression (increased uptake of FDG-PET/CT, increased tumor volume, changes in laboratory examinations and clinical symptoms), death or last follow-up. OS was defined from diagnosis to the date of death or last follow-up. Survival curve was plotted by KaplanMeier curves, and differences between groups were compared by log-rank test. The multivariate survival analysis was performed using the Cox proportional hazards model. OS was only analyzed with baseline PET/CT due to the small number of events. Differences in sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) were compared using McNemar's test. Differences in ΔSUV max % between different clinical outcomes were assessed using the Mann-Whitney U-test. A p-value of <0.05 was considered as statistically significant. a median time of 24 months (range of 2-42 months), and five patients died with a median time of 24 months (range of 2-36 months). Table 2 lists the differences in clinical characteristics among the dichotomized tMTV, TLG and SUV max groups. Pearson chi-square test and Fisher's exact test showed that the LDH level and FLIPI score were significantly associated with tMTV, TLG and SUV max , whereas Ann Arbor stage, bone marrow biopsy, LodLIN (cm) and number of involved nodes were significantly associated with a higher tMTV and TLG, but not SUV max . B symptoms and ECOG were significantly associated with a higher SUV max , but not tMTV and TLG. Meanwhile, the number of extranodal sites was significantly associated with a higher tMTV and SUV max , but not TLG.
Results

Characteristics and outcomes of patients
Correlation between clinical characteristics with semi-quantitative parameters
Spearman correlation test showed that the Ann Arbor stage, number of extranodal sites, LDH level, FLIPI score, LodLIN (cm) and number of involved nodes were positively and significantly associated with SUV max , tMTV or TLG, whereas bone marrow biopsy was positively and significantly associated with tMTV or TLG, but not SUV max . On the other hand, there was a positive and significant association among SUV max , tMTV and TLG. (Table 3 ) Role of 18 Table 4 summarizes the baseline PET/CT metabolic parameters for SUV max , tMTV and TLG. According to the Kaplan-Meier curve and the log-rank test, patients with high levels of tMTV and TLG had poorer clinical survival compared with those with low levels of tMTV and TLG , p=0.003). Patients with a high level of TLG had a 2-year PFS rate of 57.14%, while it became 95.56% in patients with a low level of TLG (cutoff value 1,364.60, p=0.0001). The 2-year OS rates of the low-and high-TLG groups were 100% and 62.50%, respectively (cutoff value 2,398.00, p<0.0001).
F-FDG PET/CT in predicting outcome
By univariate analysis (Table 5) , we found that Ann Arbor stage (p=0.015), SUV max (p=0.043), tMTV (p=0.005), TLG (p=0.000), number of extranodal sites (p=0.035) and bone marrow biopsy (p=0.019) were significantly associated with PFS.
The tMTV (p=0.003), TLG (p<0.0001), ECOG (p=0.009) and bone marrow biopsy (p=0.050) were significantly associated with OS. Multivariate analysis showed ( 
Interim PET/CT Prognostic impact of D-5PS and IHP criteria
A total of 24 patients underwent I-PET after 3-4 cycles of chemotherapy (median of four cycles), among which 15 patients underwent I-PET after four cycles of chemotherapy, and nine patients were imaged after three cycles of chemotherapy. Kaplan-Meier survival analysis demonstrated that I-PET, using any of the evaluation criteria (D-5PS or IHP), was not a prognostic factor for PFS (p>0.05, Figure 4) . By using the D-5PS criteria, 10 Figure 5 ). According to IHP criteria, 12 (50%) patients achieved CR. IHP-negative patients showed a higher PFS rate compared with IHPpositive patients, while the difference was not statistically significant (91.67 vs 75%, p=0.186, Table 7 , Figure 5 ). criteria, while the sensitivity (80% vs 80%) was similar between two criteria (all p>0.05).
Prognostic impact of ΔSUV max %
Of the 24 patients, 15 patients underwent baseline and interim PET/CT scans, and the ΔSUV max % between I-PET and B-PET was significantly different between the progression (n=4) and progression-free groups (n=11) (59.34% vs 76.22%, p=0.361).
The ROC analysis showed that the optimal cutoff point was 66.95% (AUC: 0.659; sensitivity: 75%; specificity: 72.73%; accuracy: 73.33%; PPV: 50%; NPV: 88.89%) when using ΔSUV max % as a predictor of progression. Patients with lower ΔSUV max % (<66.95%) had low PFS compared with those with higher ΔSUV max % (>66.95%), while the difference was not statistically significant (66.67% vs 88.89%, χ 2 =2.096, p=0.148, Figure 6 ).
End-of treatment PET/CT Prognostic impact of D-5PS and IHP criteria
A total of 43 patients underwent end-of treatment PET/CT after all planned first-line therapy. By using the D-5PS criteria, 14 (32.56%) patients were categorized as score 4-5, and 29 (67.44%) patients were categorized as score 1-3. According to IHP criteria, 22 (51.16%) patients showed CR. In patients with a negative PET/CT, the 2-year PFS rates for the D-5PS and IHP criteria were 93.10% and 95.45%, respectively, compared with the corresponding values of 35.71% and 57.14% in patients with a positive PET/CT, respectively (p=0.0001 for D-5PS, and p=0.006 for IHP, Figures 4 and 7) . D-5PS criteria had a better specificity (86.21% vs 65.52%), accuracy (81.40% vs 69.77%) and PPV (71.43% vs 52.38%) compared with IHP criteria (all p<0.05), while its sensitivity (7 1.43% vs 78.57%) and NPV (86.21% vs 86.36%) were slightly lower (all p>0.05, Table 8 ).
Prognostic impact of ΔSUV max %
Of the 43 patients, 28 patients underwent both baseline and end-of treatment PET/CT scans, and the ΔSUV max % between E-PET and B-PET was significantly different between the progression (n=14) and progression-free groups (n=14) (41.70% vs 82.34%, p=0.003).
The ROC analysis showed that the optimal cutoff point was 68.97% (AUC: 0.848; sensitivity: 77.78%; specificity: 89.47%; accuracy: 85.71%; PPV: 77.78%; NPV: 89.47%) when using ΔSUV max % as a predictor of progression. Patients with lower ΔSUV max % (<68.97%) had significantly lower PFS compared with those with higher ΔSUV max % (>68.97%) (22.2% vs 89.5%, χ 2 =13.774, p=0.0002, Figure 6 ). 
Discussion
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F-FDG PET/CT is currently a standard imaging technology for diagnosis, staging and prediction of prognosis in patients with HL or NHL. 6, 20 Over 95% of FL is FDG uptake. 21 PET/CT is recommended for initial evaluation, staging and response assessment of FL in the Lugano 2014 International Conference on Malignant Lymphoma imaging consensus guidelines. 22 However, the data of PET/ CT in the baseline, interim and end-of treatment of adult FL patients are very limited. In the present study, we demonstrated that both baseline tMTV and TLG had the potential to predict PFS and OS for FL patients. Ann Arbor stage, number of extranodal sites, LDH level, FLIPI score, LodLIN (cm), number of involved nodes and bone marrow biopsy were positively and significantly associated with tMTVor TLG. Furthermore, TLG was the independent prognostic factor of PFS and OS. MTV and TLG included both anatomical and metabolic features, and have shown that high TLG is the only independent factor for predicting survival in extranodal nasal type NK/T cell lymphoma. Combination of early PET/CT response and baseline MTV or TLG improves the predictive power of interim PET in DLBCL. 24 Other studies have also demonstrated the significant prognostic values of MTV and TLG in FL. 1, 25 Cottereau et al 26 have found that MTV is an independent predictor of PFS and OS in patients with high-tumor burden FL. A pooled analysis consisting of 185 patients with hightumor burden FL indicates that baseline tMTV is an independent predictor of PFS. 1 Although we found the relationship between tMTV and prognosis in univariate analysis, the multivariate analysis indicated that TLG was an independent predictive factor of PFS and OS. This discrepancy might be attributed to many factors. First, TLG was not included in their study. Furthermore, PET/CT had low sensitivity when detecting bone marrow involvement, which might affect the calculation of tMTV. 27 Last, the distributions of risk groups in patients were different. Recent studies have shown that the optimal cutoff points for total MTV are different. 1, 25, 28 with bulky disease (>5 cm). Another factor affecting tMTV cutoff is the different ways used to measure the marginal threshold. In our study, the tMTV was measured using the 41% SUV max threshold recommended by the European Association of Nuclear Medicine guidelines because of its high inter-observer reproducibility. 16 However, tMTV is measured using absolute values (2.0, 2.5 and 3.0) as the threshold in Song 28 and Liang 25 's studies. As previously reported, absolute threshold, such as SUV ≥2.5, may underestimate the volume of lesions with low SUV, which is less than the threshold value. 29 Although our cutoff value was different, tMTV and TLG were robust prognostic indicators of patient survival.
Recently, the prognostic role of I-PET has been emphasized. [30] [31] [32] Lu et al 31 have conducted a retrospective analysis on 57 FL patients (grade 1, 2 and 3a), and demonstrated a poor prognostic value for the IHP criteria in F-FDG-PET/CT cannot detect these cells. 18 In addition, the follow-up time, the patient population, the treatment regimen, and the number of chemotherapy cycles can all cause these controversies. 33 The utility of PET/CT in assessing response after endof treatment has been confirmed in several studies. 6, 11, 19, 32 In accordance with previous findings, our study confirmed that E-PET had predictive value for PFS in FL patients, and PFS in PET-positive patients was significantly lower compared with PET-negative patients. However, only very few studies have investigated the relationship between PET/CT results and OS at the end-of treatment. 13 In our present study, a small number of patients died for progressive FL, and the OS was not analyzed. Therefore, the role of E-PET in FL remains controversial. Visual interpretation of D-5PS seems to be a better prognostic value than IHP criteria, with a higher referenced background (liver). 12, [34] [35] [36] In our study, we found that the D-5PS criteria had a higher specificity, PPV and accuracy compared with the IHP criteria in the interim and the end-of treatment. Interestingly, we also found that the specificity, accuracy and PPV of PET/CT at the end-of chemotherapy, regardless of D-5PS or IHP criteria, were significantly higher compared with interim PET/CT. This finding was consistent with previous conclusions, 37 indicating that E-PET might have a stronger diagnostic value than I-PET. However, additional studies are still necessary. The percentage of ΔSUV max is a semi-quantitative method with excellent inter-observer agreement and improved prognostic value of I-PET 38, 39 and E-PET. 40, 41 Rossi et al 38 have performed an interim PET/CT after two cycles of chemotherapy in HL patients, and shown a promising prognostic value using the criteria of ΔSUV max % >71%. Itti et al 40 have found that ΔSUV max % >72.9% is an important predictor of PFS at the end of treatment in DLBCL patients. In our study, we found that ΔSUV max % using a cutoff of 68.97% had predictive value for FL patients after first-line chemotherapy. However, we failed to show a better predictive value for interim PET/ CT when using a cutoff value of 66.95%. To the best of our knowledge, studies on the evaluation criteria of ΔSUV max % in FL patients are limited, and a large number of prospective studies are required. There are some limitations and shortcomings in this study. This was a single-center retrospective study, in which only 59 patients underwent PET/CT scans before treatment, only 24 patients had 2-4 cycles of chemotherapy, and only 43 patients had all planned first-line therapy. Since a significant proportion of patients had a good therapeutic response after chemotherapy and a small number of patients died for progressive FL, the OS was not analyzed with I-PET and E-PET.
Conclusion
Collectively, we demonstrated that baseline TLG was an independent predictor of PFS and OS in FL. E-PET results using D-5PS and IHP criteria were significantly associated with PFS, whereas I-PET results were not associated with PFS. D-5PS criteria showed a better sensitivity, accuracy and PPV compared with IHP criteria in I-PET or E-PET. In addition, the ΔSUV max % from the baseline to the end-of therapy could be used for precise prediction of patient prognosis.
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